Concord Drugs Ltd vs Wockhardt Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 81.54 as of 12 May 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.7 on March 2021 to 6.7 on March 2021 . This represents a CAGR of 0.00% over 1 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 3800 crore on March 2022 to ₹ 4590 crore on March 2021 . This represents a CAGR of 3.85% over 5 years The revenue of Concord Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 16.99 crore. This represent the decline of -100% The revenue of Wockhardt Ltd for the Mar '26 is ₹ 1032 crore as compare to the Dec '25 revenue of ₹ 913 crore. This represent the growth of 13.03% The ebitda of Concord Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0.94 crore. This represent the decline of -100% The ebitda of Wockhardt Ltd for the Mar '26 is ₹ 292 crore as compare to the Dec '25 ebitda of ₹ 192 crore. This represent the growth of 52.08% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Wockhardt Ltd changed from ₹ -16 crore to ₹ 164 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Wockhardt Ltd

Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

FAQs for the comparison of Concord Drugs Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Wockhardt Ltd?

Market cap of Concord Drugs Ltd is 110 Cr while Market cap of Wockhardt Ltd is 26,463 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Wockhardt Ltd?

The stock performance of Concord Drugs Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Wockhardt Ltd?

As of May 12, 2026, the Concord Drugs Ltd stock price is INR ₹84.18. On the other hand, Wockhardt Ltd stock price is INR ₹1628.6.

How do dividend payouts of Concord Drugs Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.